ICI-induced Granulomatous Sialadenitis is Responsive to Prednisone
Preprint
Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but commonly cause immune-related adverse events (irAEs), whether administered as monotherapy or in combination with other oncological agents. We present the first reported case of ICI-induced granulomatous sialadenitis in a male patient in his mid-fifties with BRAF-V600E-mutated papillary thyroid carcinoma who received sequential treatment with BRAF/MEK inhibitors followed by pembrolizumab. The patient experienced acute-onset severe xerostomia and salivary hypofunction, prompting ICI cessation and salivary gland biopsy. Integrative analysis using histology, single-cell RNA sequencing, and spatial transcriptomics revealed macrophage- and T-cell-mediated epithelial damage driven by epithelial senescence and Th1-polarized inflammation. Corticosteroid therapy reduced granuloma burden and improved salivary flow rates and tissue architecture; however, extensive fibrosis persisted despite treatment. These findings underscore the critical importance of early irAE recognition and intervention to preserve glandular function and enable continuation of cancer therapy.Keywords
This publication has 9 references indexed in Scilit:
- A transcriptome-based human universal senescence index (hUSI) robustly predicts cellular senescence under various conditionsNature Aging, 2025
- Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck CancerJAMA Oncology, 2025
- Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid CarcinomaThyroid®, 2024
- BRAF inhibition and the spectrum of granulomatous reactionsJournal of the American Academy of Dermatology, 2022
- Sicca Syndromes2021
- Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint InhibitorFrontiers in Oncology, 2020
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor TherapyThe Oncologist, 2019
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaClinical Cancer Research, 2013